Abstract: The invention provides polynucleotides isolated from cDNA libraries of human fetal liver-spleen and macrophage as well as polypeptides encoded by these polynucleotides and mutants or variants thereof. The polypeptides correspond to a human CD39-like protein. Other aspects of the invention include vectors containing polynucleotides of the invention and related host cells as well a processes for producing CD39-like polypeptides, and antibodies specific for such polypeptides.
Type:
Grant
Filed:
August 9, 1999
Date of Patent:
September 10, 2002
Assignee:
Hyseq, Inc.
Inventors:
John Ford, Julio J. Mulero, George Yeung
Abstract: The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described.
Abstract: The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components.
Type:
Grant
Filed:
September 14, 1999
Date of Patent:
August 13, 2002
Assignee:
Antigen Express, Inc.
Inventors:
Robert E. Humphreys, Sharlene Adams, Minzhen Xu
Abstract: This invention relates to therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids, and on the role of their signaling pathway in endothelial cell migration and/or differentiation. In addition, this invention provides a substantially purified Jagged protein, as well as a substantially purified nucleic acid molecule or segment thereof encoding Jagged protein, or a functionally equivalent derivative, or allelic or species variant thereof.
Type:
Grant
Filed:
November 25, 1998
Date of Patent:
August 13, 2002
Assignee:
Maine Medical Center Research Institute
Inventors:
Ann B. Zimrin, Michael Wong, Thomas Maciag, Michael S. Pepper, Roberto Montesano
Abstract: The invention involves the identification of peptides which complex with HLA-Cw*16 molecules, and which may then provoke lysis of the cells to which they bind, by cytolytic T cells. Diagnostic and therapeutic uses are described.
Type:
Grant
Filed:
February 1, 2000
Date of Patent:
August 6, 2002
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Pierre van der Bruggen, Etienne DePlaen, Thierry Boon-Falleur
Abstract: The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.
Type:
Grant
Filed:
November 15, 1999
Date of Patent:
July 9, 2002
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Danila Valmori, Jean-Charles Cerrotini, Pedro Romero
Abstract: Podocalyxin like proteins (e.g. PCLP and PCLP-2) having selectin ligand activity are provided. Also provided are nucleic acid compositions encoding novel PCLP-2 proteins. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies for disease conditions associated with podocalyxin like protein activity. In particular, methods of treating diseases associated with podocalyxin like protein selectin binding activity and/or chemokine presenting activity are provided, where such diseases include inflammation and the like.
Type:
Grant
Filed:
February 3, 1999
Date of Patent:
May 28, 2002
Assignee:
The Regents of the University of California
Inventors:
Steven D. Rosen, Christopher M. Sassetti
Abstract: The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.
Type:
Grant
Filed:
May 1, 1998
Date of Patent:
May 28, 2002
Assignee:
Immunomedics, Inc.
Inventors:
Susanna M. Rybak, Dianne L. Newton, David M. Goldenberg
Abstract: Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
Type:
Grant
Filed:
June 2, 1999
Date of Patent:
May 21, 2002
Assignee:
Adherex Technologies, Inc.
Inventors:
Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
Abstract: The invention provides novel polynucleotides isolated from cDNA libraries of human fetal liver-spleen and macrophage as well as polypeptides encoded by these polynucleotides and mutants or variants thereof. The polypeptides correspond to a novel human CD39-like protein. Other aspects of the invention include vectors containing polynucleotides of the invention and related host cells as well a processes for producing novel CD39-like polypeptides, and antibodies specific for such polypeptides.
Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
Type:
Grant
Filed:
December 14, 1999
Date of Patent:
May 7, 2002
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Danila Valmori, Jean-Charles Cerottini, Pedro Romero
Abstract: This invention is based on the discovery that an essentially nonallergenic covalent conjugate of a model allergen, ovalbumin (OA), and monomethoxypolyethylenc glycol (mPEG) is capable of inactivating in vivo and ex vivo granulocytes sensitized with anti-OA IgE antibodies (Abs). As a result of the inactivation of the granulocytes, subsequent challenge with OA was not followed by degranulation and the consequent release of the mediators of anaphylaxis (vasoactive compounds) from the granules of these cells. These results, therefore, provide a basis for the treatment of symptoms of an already established immune response against an allergen or allergens.
Abstract: Disclosed are compositions and methods for accelerating the differentiation of human MSCs into the osteogenic lineage with resultant enhanced de novo bone formation. This makes possible improved methods for bone defect repair. Thus, one aspect of the invention is a method for accelerating the differentiation of ALCAM-bearing hMSCs into the osteogenic lineage by contacting such hMSCs with a ligand that binds to activated leukocyte-cell adhesion molecule (ALCAM) on a single hMSC. Preferably, the ligand is a Fab fragment of a monoclonal antibody expressed by the hybridoma of ATCC Accession No. NB 11789.
Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
Type:
Grant
Filed:
October 5, 1999
Date of Patent:
April 9, 2002
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Danila Valmori, Jean-Charles Cerottini, Pedro Romero
Abstract: Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof are used in pharmaceutical preparations and in diagnosis. Cells which express these antibodies, antibody fragments, mixtures or derivatives thereof are also disclosed.
Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
Abstract: Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.
Type:
Grant
Filed:
June 10, 1997
Date of Patent:
March 12, 2002
Assignee:
Viventia Biotech Inc.
Inventors:
Mark C. Glassy, Helena R. Chang, Keiji Koda
Abstract: The current invention relates to an active factor present in homogenized brain tissue which inhibits antigen-driven proliferation of lymphocytes in culture, but stimulates proliferation in response to most mitogens. The inhibitory activity can be destroyed by treatment with proteases or neuraminadase. The activity is in the insoluble fraction of the homogenate, but becomes soluble in 0.04 M NaOH. After gel filtration chromatography of the NaOH soluble material, the suppressive activity is in the high molecular weight fraction which elutes in the void volume of the column. This fraction contains protein and carbohydrate. The activity is not affected by neutralizing antibodies against regulatory cytokines, does not depend on Fas or FasL, and is not due to the presence of gangliosides. These data suggest that a brain glycoprotein which is either membrane-bound or part of the extracellular matrix has powerful immune regulatory effects in culture.
Abstract: The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. In particular, the polypeptides and polynucleotides of the invention comprise amino acid and nucleic acid sequences of novel CD39-like gene and gene products.
Type:
Grant
Filed:
January 29, 1999
Date of Patent:
February 26, 2002
Assignee:
HYSEQ, Inc.
Inventors:
Brian Paul Chadwick, Anna-Maria Frischauf